Literature DB >> 11271253

Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC.

J H Bruning1, M Persoons, K Lemström, F S Stals, E De Clercq, C A Bruggeman.   

Abstract

Effects of acute cytomegalovirus (CMV) infections on transplantation-associated atherosclerosis (TxAA) were studied in a rat model for chronic vascular rejection. Rats underwent orthotopic abdominal allogeneic aorta transplantation. Neo-intima formation and media thinning was quantitated by measurement of cross-sectional surface areas (CSA) at day 50 post transplantation (Tx). Acute rat cytomegalovirus (RCMV) infection, established at the moment of maximum intimal proliferation and influx of inflammatory cells in the adventitia, resulted in enhanced neo-intima formation, accompanied by increased influx and proliferation of smooth muscle cells (smc) in the intima. This effect was completely inhibited by HPMPC, a very potent and selective inhibitor of CMV replication, indicating the virus specificity of the measured effects. Despite increased neointima formation, media thinning ("necrosis") was not affected by RCMV infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 11271253     DOI: 10.1111/j.1432-2277.1994.tb01393.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  13 in total

1.  Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells.

Authors:  Cynthia A Bolovan-Fritts; Rodney N Trout; Stephen A Spector
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 2.  Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection.

Authors:  Michael L Freeman; Michael M Lederman; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

3.  High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage.

Authors:  Cynthia A Bolovan-Fritts; Rodney N Trout; Stephen A Spector
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

4.  Cytomegalovirus-induced effector T cells cause endothelial cell damage.

Authors:  Pablo J E J van de Berg; Si-La Yong; Ester B M Remmerswaal; René A W van Lier; Ineke J M ten Berge
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

Review 5.  Cytomegalovirus and HIV: A Dangerous Pas de Deux.

Authors:  Sara Gianella; Scott Letendre
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

6.  Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction.

Authors:  Cynthia A Bolovan-Fritts; Stephen A Spector
Journal:  Blood       Date:  2007-09-25       Impact factor: 22.113

7.  Cytomegalovirus CC chemokine promotes immune cell migration.

Authors:  Jennifer Vomaske; Michael Denton; Craig Kreklywich; Takeshi Andoh; Jessica M Osborn; Daniel Chen; Ilhem Messaoudi; Susan L Orloff; Daniel N Streblow
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

8.  Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing.

Authors:  Jerome Dumortier; Daniel N Streblow; Ashlee V Moses; Jon M Jacobs; Craig N Kreklywich; David Camp; Richard D Smith; Susan L Orloff; Jay A Nelson
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

Review 9.  Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing.

Authors:  D N Streblow; J Dumortier; A V Moses; S L Orloff; J A Nelson
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

10.  Enhanced cytomegalovirus infection in atherosclerotic human blood vessels.

Authors:  Pamela L Nerheim; Jeffery L Meier; Mohammad A Vasef; Wei-Gen Li; Ling Hu; James B Rice; Daniel Gavrila; Wayne E Richenbacher; Neal L Weintraub
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.